Trial results

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

NCT02465515 on ClinicalTrials.gov · last registry update 2019-03-06

An unusually large phase 4: 9,463 participants, more than double the 72 typical for the stage. The sponsor logged completion for 20 February 2018. Primary outcome, as filed: Time to First Occurrence of Major Adverse Cardiovascular Events (MACE) During Cardiovascular (CV) Follow-up Time Period. albiglutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.

Status

COMPLETED

Phase

P4

Drug

albiglutide

Tanzeum

Sponsor

GlaxoSmithKline

Sponsor type

Industry

Enrollment

9,463

Started

2015-07-01

Primary completion

2018-02-20 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Time to First Occurrence of Major Adverse Cardiovascular Events (MACE) During Cardiovascular (CV) Follow-up Time Period

Conditions studied

Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the albiglutide page for this molecule’s full trial and approval history.